allsci

[allsci @allsci_corp]

https://t.co/Z8k1arYY3O

[allsci @allsci_corp]

Takeda commits up to $600M to Insilico's https://t.co/GaDOB39vGe for drug discovery—the pharma giant's third major AI platform deal in months, signaling a strategic shift toward outsourced AI-driven R&D. #AI #DrugDiscovery #Pharma

[allsci @allsci_corp]

https://t.co/B3pLJF2qwN

[allsci @allsci_corp]

Roche's divarasib becomes first KRAS G12C inhibitor to beat approved rivals in head-to-head Phase III trial, showing superior PFS and OS in second-line NSCLC. A potential game-changer for the ~14% of patients with G12C mutations. #Oncology #KRAS #NSCLC

[allsci @allsci_corp]

https://t.co/QbChuqBsIv

[allsci @allsci_corp]

Nippon Shinyaku opts into Elixirgen's full-length dystrophin mRNA (EXG-7001) for DMD—a mutation-agnostic approach distinct from exon-skipping and gene therapy. IND filing imminent. #DMD #mRNA #RareDisease

[allsci @allsci_corp]

https://t.co/TkUWtqgZrq

[allsci @allsci_corp]

Ipsen acquires Kartos for navtemadlin, an oral MDM2 inhibitor in Phase III for myelofibrosis. The p53-reactivating combo therapy targets ruxolitinib-suboptimal patients, with POIESIS data expected 2027. Deal valued up to $1.75B. #Oncology #Pharma #Myelofibrosis

[allsci @allsci_corp]

https://t.co/cNJ19LR6kZ

[allsci @allsci_corp]

Zymeworks to acquire Theravance for $929M, securing Yupelri's $60M annual cash flows via non-recourse financing. Deal adds commercial-stage respiratory asset + $2.5B Irish tax attributes while preserving balance sheet flexibility. #Biotech #M&A #COPD

[allsci @allsci_corp]

https://t.co/ZgKIjqkCAw

[allsci @allsci_corp]

Rare reversal: CHMP backs trofinetide for Rett syndrome after initial rejection, paving the way for the EU's first approved pharmacological therapy for the rare neurological disorder. #RareDiseases #EMA #Pharma

[allsci @allsci_corp]

https://t.co/6CyNXDZQCU

[allsci @allsci_corp]

Remix Therapeutics goes public via Passage Bio reverse merger, securing $100M PIPE. Lead asset REM-422 showed 43% ORR in ACC patients at ASCO 2026—a cancer with zero approved systemic therapies. Trading as RMTX on Nasdaq. #Biotech #Oncology #ClinicalTrial

[allsci @allsci_corp]

https://t.co/svXcDh7fcz

[allsci @allsci_corp]

Novartis commits up to $1.9B to Antares Therapeutics' covalent chemistry platform targeting undruggable oncology candidates. One of the largest upfront payments for a discovery-stage oncology collaboration this year. #Biotech #Oncology #DrugDiscovery

[allsci @allsci_corp]

https://t.co/pfUug3ymuk

[allsci @allsci_corp]

Merck KGaA to acquire Bio-Techne for $11.3B—its largest deal ever. The Minneapolis biotech firm's recombinant proteins, antibodies & immunoassay platforms strengthen Merck's life sciences dominance. Deal closes late 2026/early 2027. #Biotech #M&A #LifeSciences

[allsci @allsci_corp]

https://t.co/s2X62MaxDZ

[allsci @allsci_corp]

Oblenio Bio closes $62M Series B to advance LBL-051, a tri-specific T-cell engager targeting CD19/BCMA/CD3 for autoimmune disease. First-in-human study expected to launch this year. #Biotech #Immunology #ClinicalTrial